Episode 19: Can Gut Bacteria Make Immunotherapy Work Better?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Episode 19: Can Gut Bacteria Make Immunotherapy Work Better?
-
ナレーター：
-
著者：
概要
In this episode of Learn Something with Thaena, we explore one of the most promising developments in microbiome oncology: whether reshaping the gut microbiome can improve response to cancer immunotherapy. We unpack the new FMT-LUMINate trial, a phase 2 study in patients with non-small cell lung cancer and melanoma, where a single dose of fecal microbiota transplant given before checkpoint inhibitor therapy was associated with striking response rates. But the most interesting finding was not simply donor bacteria “engrafting.” Instead, responders appeared to lose specific baseline bacterial species linked to resistance, suggesting that therapeutic benefit may come from removing deleterious microbes and restoring a more immune-supportive metabolic environment. We also discuss the earlier studies that built this field, the role of antibiotics, and why metabolites, not just microbes, may be the real mechanistic story.
Paper referenced:
Duttagupta S, Messaoudene M, Hunter S, et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nature Medicine. 2026. doi:10.1038/s41591-025-04186-5.